221 related articles for article (PubMed ID: 17655680)
21. Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer.
Tcherkassova J; Abramovich C; Moro R; Chen C; Schmit R; Gerber A; Moro R
Tumour Biol; 2011 Aug; 32(4):831-8. PubMed ID: 21625941
[TBL] [Abstract][Full Text] [Related]
22. Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer.
An HJ; Miyamoto S; Lancaster KS; Kirmiz C; Li B; Lam KS; Leiserowitz GS; Lebrilla CB
J Proteome Res; 2006 Jul; 5(7):1626-35. PubMed ID: 16823970
[TBL] [Abstract][Full Text] [Related]
23. The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer.
Barlow TS; Przybylski M; Schilder JM; Moore DH; Look KY
Int J Gynecol Cancer; 2006; 16(2):496-500. PubMed ID: 16681717
[TBL] [Abstract][Full Text] [Related]
24. On the analysis of glycomics mass spectrometry data via the regularized area under the ROC curve.
Ye J; Liu H; Kirmiz C; Lebrilla CB; Rocke DM
BMC Bioinformatics; 2007 Dec; 8():477. PubMed ID: 18076765
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer.
Simon I; Liu Y; Krall KL; Urban N; Wolfert RL; Kim NW; McIntosh MW
Gynecol Oncol; 2007 Jul; 106(1):112-8. PubMed ID: 17490732
[TBL] [Abstract][Full Text] [Related]
26. The effect of CA125 on metastasis of ovarian cancer: old marker new function.
Yuan Q; Song J; Yang W; Wang H; Huo Q; Yang J; Yu X; Liu Y; Xu C; Bao H
Oncotarget; 2017 Jul; 8(30):50015-50022. PubMed ID: 28637006
[TBL] [Abstract][Full Text] [Related]
27. Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients.
Pochechueva T; Chinarev A; Schoetzau A; Fedier A; Bovin NV; Hacker NF; Jacob F; Heinzelmann-Schwarz V
PLoS One; 2016; 11(10):e0164230. PubMed ID: 27764122
[TBL] [Abstract][Full Text] [Related]
28. LyGDI is a promising biomarker for ovarian cancer.
Zhen H; Yang S; Wu H; Wang S; Lv J; Ma L; Zhang X
Int J Gynecol Cancer; 2010 Apr; 20(3):316-22. PubMed ID: 20375790
[TBL] [Abstract][Full Text] [Related]
29. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
[TBL] [Abstract][Full Text] [Related]
30. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
Li QL; Wang CJ; Qi P; Zhang YX
Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
[TBL] [Abstract][Full Text] [Related]
31. The glycolyzer: automated glycan annotation software for high performance mass spectrometry and its application to ovarian cancer glycan biomarker discovery.
Kronewitter SR; De Leoz ML; Strum JS; An HJ; Dimapasoc LM; Guerrero A; Miyamoto S; Lebrilla CB; Leiserowitz GS
Proteomics; 2012 Aug; 12(15-16):2523-38. PubMed ID: 22903841
[TBL] [Abstract][Full Text] [Related]
32. Performance of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) in diagnosis of ovarian cancer: a systematic review and meta-analysis.
Li K; Pei Y; Wu Y; Guo Y; Cui W
J Ovarian Res; 2020 Jan; 13(1):6. PubMed ID: 31924227
[TBL] [Abstract][Full Text] [Related]
33. New tumor markers: CA125 and beyond.
Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
[TBL] [Abstract][Full Text] [Related]
34. Clinical value of a new serum tumor marker, CA125II, in gynecologic disease: comparison with CA125.
Tamakoshi K; Kikkawa F; Hasegawa N; Ishikawa H; Mizuno K; Kawai M; Tomoda Y
Gynecol Obstet Invest; 1995; 39(2):125-9. PubMed ID: 7737582
[TBL] [Abstract][Full Text] [Related]
35. Biomarker discovery for ovarian cancer using SELDI-TOF-MS.
Zhang H; Kong B; Qu X; Jia L; Deng B; Yang Q
Gynecol Oncol; 2006 Jul; 102(1):61-6. PubMed ID: 16403569
[TBL] [Abstract][Full Text] [Related]
36. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
[TBL] [Abstract][Full Text] [Related]
37. [Identification of serum peptide biomarker for ovarian cancer diagnosis by Clin-TOF-II-MS combined with magnetic beads technology].
Xiu L; Li N; Wang WP; Chen F; Yuan GW; Sun YC; Zhang R; Li XG; Zuo J; Li N; Cui W; Wu LY
Zhonghua Zhong Liu Za Zhi; 2021 Nov; 43(11):1188-1195. PubMed ID: 34794222
[No Abstract] [Full Text] [Related]
38. A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer - An international multicenter study in women with an ovarian mass.
Karlsen MA; Høgdall EV; Christensen IJ; Borgfeldt C; Kalapotharakos G; Zdrazilova-Dubska L; Chovanec J; Lok CA; Stiekema A; Mutz-Dehbalaie I; Rosenthal AN; Moore EK; Schodin BA; Sumpaico WW; Sundfeldt K; Kristjansdottir B; Zapardiel I; Høgdall CK
Gynecol Oncol; 2015 Sep; 138(3):640-6. PubMed ID: 26086566
[TBL] [Abstract][Full Text] [Related]
39. Estimation of the usefulness of neoplastic markers TPS and CA 125 in diagnosis and monitoring of ovarian cancer.
Zygmunt A; Madry R; Markowska J; Fischer Z
Eur J Gynaecol Oncol; 1999; 20(4):298-301. PubMed ID: 10475127
[TBL] [Abstract][Full Text] [Related]
40. Comparative profiling of N-glycans isolated from serum samples of ovarian cancer patients and analyzed by microchip electrophoresis.
Mitra I; Alley WR; Goetz JA; Vasseur JA; Novotny MV; Jacobson SC
J Proteome Res; 2013 Oct; 12(10):4490-6. PubMed ID: 23984816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
